RESEARCH ARTICLE

Sequence Variations and Protein Expression Levels of the Two Immune Evasion Proteins Gpm1 and Pra1 Influence Virulence of Clinical Candida albicans Isolates

Shanshan Luo¹*, Uta-Christina Hipler², Christin Münzberg¹, Christine Skerka¹, Peter F. Zipfel¹, ³*

¹ Department of Infection Biology, Leibniz-Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute, Jena, Germany, ² Friedrich-Schiller-University Hospital, Clinic of Dermatology and Allergology, Jena, Germany, ³ Friedrich-Schiller-University, Jena, Germany

¤ Current address: Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, München, Germany

* peter.zipfel@hki-jena.de

Abstract

Candida albicans, the important human fungal pathogen uses multiple evasion strategies to control, modulate and inhibit host complement and innate immune attack. Clinical C. albicans strains vary in pathogenicity and in serum resistance, in this work we analyzed sequence polymorphisms and variations in the expression levels of two central fungal complement evasion proteins, Gpm1 (phosphoglycerate mutase 1) and Pra1 (pH-regulated antigen 1) in thirteen clinical C. albicans isolates. Four nucleotide (nt) exchanges, all representing synonymous exchanges, were identified within the 747-nt long GPM1 gene. For the 900-nt long PRA1 gene, sixteen nucleotide exchanges were identified, which represented synonymous, as well as non-synonymous exchanges. All thirteen clinical isolates had a homozygous exchange (A to G) at position 73 of the PRA1 gene. Surface levels of Gpm1 varied by 8.2, and Pra1 levels by 3.3 fold in thirteen tested isolates and these differences influenced fungal immune fitness. The high Gpm1/Pra1 expressing candida strains bound the three human immune regulators more efficiently, than the low expression strains. The difference was 44% for Factor H binding, 51% for C4BP binding and 23% for plasminogen binding. This higher Gpm1/Pra1 expressing strains result in enhanced survival upon challenge with complement active, Factor H depleted human serum (difference 40%). In addition adhesion to and infection of human endothelial cells was increased (difference 60%), and C3b surface deposition was less effective (difference 27%). Thus, variable expression levels of central immune evasion protein influences immune fitness of the human fungal pathogen C. albicans and thus contribute to fungal virulence.
Introduction

The human pathogenic yeast *Candida albicans* is frequently isolated from individuals with fungal infections. This dimorphic fungal pathogen causes superficial, as well as systemic, infections and is frequently isolated from patients who undergo immunosuppressive therapy or long-term catheterization [1,2,3]. In infected individuals, *Candida* is identified in blood, brain, eye, kidney, heart, as well as lung, liver, and spleen. The symptoms of *Candida* infection vary to a great extent and depend on the site of infection. Oral candidiasis develops characteristic thick, white lacy patches on top of a red base, which may induce inflammatory reactions on the tongue, as evidenced by the red color, sometimes even without any white coating [4]. Vaginal infections represent as white cheesy discharge, which irritates the internal and also the surrounding outer tissues [5]. Even with the use of anti-fungal therapy, both mortality and morbidity by *C. albicans* infections remain unacceptably high and over 75% of patients with systemic *Candida* infection die [6,7,8]. Moreover, the rate of treatment-resistant *C. albicans* strains has been steadily increasing, while vaccination development has remained challenging and lagging [9]. Therefore, a detailed characterization of *C. albicans* virulence factors is necessary not only for understanding the process of infection in detail but also for generating new and more effective anti-fungal compounds.

Complement is a central innate immune surveillance system, that acts as the first line of innate immune defense [10]. Upon infection the host complement system is activated within seconds [11] and the activated system generates several immune effector molecules which coordinate immune response, cell infiltration and have toxic effects on the target. Based on these toxic effects, activation and processing of this important defense system is tightly regulated by both fluid phase and surface associated regulators. The proper and coordinated action of these regulators is important for maintaining homeostasis and to efficiently protect the human organism from infections agents [12,13,14,15,16,17,18]. Thus, in order to survive and establish an infection the human fungal pathogen *C. albicans*, similar to other human pathogenic fungus, acquires human plasma proteins and complement regulators, including Factor H, FHL-1 (factor H like protein 1) and C4BP (C4 binding protein), as well as plasminogen [19,20,21,22]. Bound to the fungal surface, these human inhibitors maintain their regulatory activity, block complement effector function(s), opsonization and phagocytosis, inhibit cascade activation, as well as cascade progression, and further inhibits the damaging, toxic and inflammatory effector functions of the activated complement system [20,21,23]. At present, four Candida Factor H/ FHL-1 binding proteins are identified, which are Gpm1, Pra1 [24,25], Hgt1p as well as Gpd2 [26,27]. Gpm1, Pra1 and Gpd2 also bind the coagulation protease and complement inhibitor plasminogen. In addition, seven other plasminogen binding proteins were identified on *C. albicans* surface via a proteome approach [28].

Many, even all infectious pathogens exploit host Factor H and plasminogen for immune evasion and for tissue penetration. In general terms, pathogenic microbes express host regulator binding proteins at their surface that bind several human immune inhibitors and proteases, like Factor H or plasminogen [29,30,31,32,33]. Microbial immune evasion displays features of multiplicity and by redundancy. Apparently a single microbial immune evasion protein binds a unique repertoire of human proteins and immune regulators, e.g. Candida Pra1 binds Factor H, FHL-1, C4BP, C3, plasminogen, and blocks cleavage and activation of C3 by a preformed C3 convertase [25,34,35]. Furthermore, Candida Pra1 also binds to the human integrin receptors CR3 and CR4 which are expressed on leukocytes [36]. In addition, a pathogenic microbe expresses several host immune regulator binding proteins at the same time. Although the different microbial immune evasion proteins which attach the same host regulator, e.g. via the same or overlapping regions, lack common sequences motives [29,30,37]. The
microbial Factor H binding proteins represent either highly polymorphic proteins, that display a high degree of sequence diversity, or they present as conserved genes, with no or even moderate sequence variation. Examples for the diverse group of microbial Factor H-plasminogen binding proteins, which display a high degree of sequence diversity, include the M protein encoding gene family of \( S \) \( pyogenes \), and the PspC protein family of \( S. \) \( pneumoniae \) \[38,39,40,41\]. Examples for the second group, with more conserved genes, are CRASPs (complement regulator-acquiring surface proteins) of \( B. \) \( Borrelia \) species and also FHBP of group B \( N. \) \( meningitidis \) isolates \[42\].

Currently, it is unclear whether the two Candida Factor H/plasminogen binding proteins Gpm1 and Pra1 represent conserved or polymorphic fungal immune evasion proteins and/or whether the expression levels of the two proteins vary among clinical Candida isolates. Therefore, we analyzed sequence variability and expression levels of the \( GPM1 \) and \( PRA1 \) genes in thirteen clinical \( C. \) \( albicans \) isolates. Here we show that the Candida \( GPM1 \)- and \( PRA1 \)- genes are conserved genes and that their expression levels varied by 8.2 fold for Gpm1 (MFI 512 to 4192) or 3.3 fold for Pra1 (MFI 12393 to 41282) respectively. This difference in Gpm1-, Pra1 surface levels influenced fungal immune fitness in terms of human regulator binding, survival in complement active, Factor H depleted human serum, adhesion to human endothelial cells, as well as \( C3b/iC3b \) surface deposition. Thus surface levels likely in combination with sequence variations influence and adjust immune fitness of Candida/fungal isolates.

**Materials and Methods**

**Study approval and collection of clinical \( C. \) \( albicans \) isolates**

The study was approved by the Ethical Board of the Medical Department of the Friedrich Schiller University in Jena, Germany. Patients provided written consent for participation in the study. In total, thirteen strains were tested. The strains had been isolated from dermatological patients (Department of Dermatology, Jena, Germany), using FungiQuick swabs (Hain lifescience, Nehren, Germany). The swabs were incubated in Sabouraud glucose bouillon included in the FungiQuick test kit (\( t = 24 \) h, room temperature). Afterwards, the yeast containing bouillon was plated onto Sabouraud glucose agar plates and incubated for 24 h at 30°C. The obtained cultures were used for species identification by the API ID 32C test system (bioMerieux) according to instructions of the manufacturer (test results were read after 24 h and 48 h).

**\( C. \) \( albicans \) strains and growth conditions**

The \( C. \) \( albicans \) wild type strains SC5314 \[43\] and different clinical isolates, which were isolated from different \( C. \) \( albicans \) infected patients were cultivated in YPD medium (2% (w/v) glucose, 2% (w/v) peptone, 1% (w/v) yeast extract) at 30°C. Yeast cells were collected by centrifugation and counted with a hemocytometer (Fein-Optik, Bad Blankenburg).

**Antibodies and anti-sera**

Polyclonal Gpm1- or Pra1 anti-sera was raised in rabbits by immunization with purified recombinant Gpm1 or Pra1 protein \[24,25\]. Polyclonal rabbit Saps1/2/3 (Secreted aspartyl proteases) anti-serum was kindly provided by Prof. Bernhard Hube (Germany). Polyclonal goat anti Factor H was purchased from CompTech, polyclonal goat anti plasminogen from Acris, and polyclonal rabbit anti-C4BP was kindly provided by Prof. Anna M. Blom (Sweden). Alexa Fluor-647 labeled goat anti-rabbit and Alexa Fluor-488 labeled rabbit anti-goat, goat anti-rabbit were all obtained from Molecular Probes used as the secondary anti-sera for flow cytometry.
Serum were collected from five healthy donors, pooled together, and stored at -80°C until use. Factor H depleted serum was prepared as described [44].

Sequence analysis

The DNA sequences of GPM1 and PRA1 from thirteen different clinical isolates and the reference strain SC5314 were amplified by PCR, sequenced and compared. Briefly, different C. albicans yeast pellets were boiled at 99°C for 10 min in H2O with 300 rpm shaking, then centrifuged at 13000 rpm for 10 min to get the supernatant which contains chromosomal DNA. These chromosomal DNA were used as the template. The GPM1 gene was amplified with forward primer: CCTTGCTCCAATTATCCTTGTAT, and reverse primer: CTACAAATCAACCCACACATCTA. Due to the long sequence, the PRA1 gene was amplified using two pairs of primers (Forward 1: TGGAAAAGACCTTTGTTTGG, Reverse 1: TTAGATTTCCGAGCGGTATA, and with Forward 2: CCAACCATAGTGATCAAATC, Reverse 2: TCTATAAAAAGATATCCATG) in order to get a precise sequence. The PCR products of both genes were first separated by the agarose gel electrophoresis, then the bands were visualized under the UV detector (GENE GENIUS 1, SYNGENE). These PCR products were purified by GFX purification kit (GE healthcare). The purified PCR products were used for sequencing with 3130x1 Genetic Analyzer using the above primers (AB applied Biosystems).

Flow cytometry

To compare Gpm1 and Pra1 surface expression level on different C. albicans strains, each of the thirteen clinical isolates and wild type SC5314 were cultivated in YPD medium overnight at 30°C. Cells were washed and incubated with polyclonal Gpm1 or Pra1 anti-serum (1:200) for 30 min on ice, followed by an Alexa Fluor-647 labeled goat anti-rabbit as a secondary anti-serum for another 30 min on ice. After washing, samples were sonicated for 10min before the fluorescence signal was determined by flow cytometry (LSR II, BD bioscience).

For Factor H, plasminogen and C4BP binding the clinical C. albicans isolates and SC5314 strain were incubated with EDTA-NHS (1:3 diluted of NHS (normal human serum) in DPBS (Dulbecco’s, buffered saline), supplemented with 10 mM EDTA to inhibit the complement activation) for 30 min at 37°C, then C. albicans cells were pellet, and re-suspended in 1% BSA in DPBS for washing, then incubated with polyclonal goat anti Factor H, rabbit anti C4BP or goat anti plasminogen sera (1:200 diluted in 1% BSA in DPBS) for 30 min on ice, followed by Alexa Fluor-488 labeled rabbit anti-goat or goat anti-rabbit as secondary anti-serum for 30 min on ice. Then the samples were washed, sonicated and examined by flow cytometry.

C. albicans survival assay

Different C. albicans clinical isolates as well as the reference strain SC5314 were cultivated in YPD medium overnight at 30°C. The yeast cells (1x10⁴/ml) were incubated with 10% Factor H depleted serum in Mg-EGTA buffer (20 mM/l HEPES, 144 mM/l NaCl, 7 mM/l MgCl₂, 10 mM/l EGTA [pH 7.4]) (which only allows activation of the alternative pathway) for 60 min at 37°C. At the time point 0 and 60 min, 10 μl of each sample were collected, transferred onto a YPD agar plate, cultivated for 2 days at 30°C. Survival of each strain was monitoring by colony counting.

Cell adhesion and invasion assay

To assay the adhesion and invasion of the six selected clinical C. albicans isolates, human endothelial cells (HUVEC) were grown to confluence on 24-well tissue culture plate (Greiner bio-
in DMEM medium (plus 10% fetal calf serum (FCS), 1% Ultra-glutamin and 0.55‰ gentamicin sulfate) at 37°C with 5% CO₂. Then the cells were incubated in FCS free medium for 24 h. After that, HUVEC were labeled by DiO (1:100) (Invitrogen) for 40 min at 37°C. The different clinical C. albicans strains were cultivated in YPD medium overnight at 30°C. Each C. albicans strain (1 x 10⁶) was washed by DPBS, and stained with calcofluor (1μg/ml) for 30 min at 37°C. Following washing, C. albicans were added to DiO labeled HUVEC cells for 2.5 h in FCS free DMEM medium. After extensive washing, cells were detached, interaction of C. albicans with HUVEC cells were measured by flow cytometry. The infected HUVEC cells were quantified by the fraction of double positive cells (DiO+, Calcofluor+).

Western blotting
The different C. albicans clinical isolates and the SC5314 strain were cultivated in the YPD medium overnight at 30°C. For each strain, the culture supernatant derived from 1x10⁶ cells was collected and treated with Roti-load 1 (Roth), separated by the SDS-PAGE and transferred to a membrane. Levels of secreted Pra1 or Sap1-Sap3 (mainly Sap2) were detected by polyclonal Pra1 or Sap1-Sap3 anti-serum, followed by a HRP-labeled swine anti-rabbit serum as a secondary antibody. The signal was detected by ECL (enhanced chemiluminescence).

C3b/iC3b surface deposition
The different clinical isolates and C. albicans strain SC5314 were cultivated in YPD medium overnight at 30°C. For each strain, the culture supernatant derived from 5x10⁶ cells were added to NHS (7.5%). The mixture was further activated by heat inactive C. albicans pellets in a Mg-EGTA buffer (100 μl) for 30 min at 37°C. After centrifugation, C3b/iC3b surface deposition on C. albicans pellet were analyzed by flow cytometry using polyclonal goat C3 anti-serum and an Alexa Fluor-488 labeled rabbit anti-goat as a secondary anti-serum.

Results

GPM1 and PRA1 sequence variations in clinical C. albicans isolates
We analyze sequence variation of two Candida immune evasion genes, GPM1 and PRA1 in thirteen clinical C. albicans isolates, which were collected from infected patients at different infection sites. Genomic DNA of each clinical strain was isolated, the corresponding GPM1- and PRA1 genes were amplified by PCR and the nucleotide sequences were determined. The 747 nt long GPM1 gene was rather conserved among these clinical isolates. The complete coding region varied at four nucleotide positions, which all result in synonymous exchanges (Fig. 1A and Table 1). The G255A exchange was identified in two isolates as a homozygous exchange and in two other isolates as a heterozygous exchange (Table 1, left panel). The C399T and C402T variations were identified in five strains as homozygous and in two strains as heterozygous exchanges. The T675A variation was present in four strains as homozygous, and in one isolate as heterozygous exchange (Table 1, left panel). Thus GPM1 has four synonymous nucleotide exchanges with a nucleotide exchange rate of 0.54%, is a relatively conserved fungal gene (Fig. 1).

GPM1 and PRA1 genes in each clinical isolate were amplified by PCR and the nucleotide sequences were determined in order to identify gene polymorphisms. Compared to the reference strain SC5314, GPM1 sequence is rather conserved, among 747-nt long open reading frame, only four nucleotides are exchange either at homozygous (A, highlighted in black) or at heterozygous scenario (A, highlighted in grey). As for the PRA1 gene, among the 900-nt open reading frame, sixteen residues were exchanged either at homozygous (marked in black) or at
heterozygous scenario (marked in grey) with different frequencies. The sequence of the PRA1 gene was more variable. Within the 900-nt long open reading frame, a total of sixteen nucleotide exchanges were identified (Fig. 1B). Nine nucleotide exchanges presented as synonymous-, and seven as non synonymous exchanges, occurring either in homozygous- or heterozygous setting (Table 1, right panel). Each clinical isolate had at least two nucleotides exchanged among the whole PRA1 sequence. Substitution of these polar uncharged N-terminally positioned Asn25, Gly105 residues to negatively charged acidic Asp25 and Asp105 residues, or of the non polar hydrophobic Ile111 to a polar Ser111 residue may be of biological relevance (Fig. 1B). The additional four non synonymous, conservative changes (i.e. Asp90Glu, Glu101Asp, Ser154Thr, as well as Asp225Glu) seem of minor or no significance.

The allelic frequency of the three non-synonymous exchanges in the PRA1 gene varied in the clinical isolates. All thirteen clinical isolates expressed the Asp25 variant in homozygous setting (Table 1). The Gly105Asp exchange was rare, one isolate had Asp105 as a homozygous, 7 non synonymous nucleotide changes which affect the protein sequence are shown in red characters. The structure of the Pra1 protein includes the signal peptide (sp), the serine rich motive (ser), as well as the putative zinc binding region (Zn). Three amino acid exchanges, result in substitution of uncharged residues (i.e. Asn25, Gly105 or Ile111 to negatively charged residues, Asp25, Asp 105 or to a polar uncharged Ser 111 (shown with blue characters). All analyzed clinical isolates had the negatively charged Asp25, in homozygocity. In addition exchange of the non polar Gly105 residue to negatively charged Asp residue occurs in some clinical isolates and exchange of the non polar Ile111 to the polar, uncharged Ser residue is identified in one single isolate (marked in blue).

doi:10.1371/journal.pone.0113192.g001
Table 1. Sequence variations of *GPM1* and *PRA1* in clinical *C. albicans* isolates.

| Isolate | Infection site | GPM1 | PRA1 |
|---------|----------------|------|------|
|         |                | G255 | C399 | C402 | T675 |
| low     |                | A73  | A210 | G240 | C270 | C288 | A303 | G314 | T332 | C387 | T411 | T460 | G475 | G600 | T603 | A654 | T765 |
| # 11    | Sacral         | GG   | CC   | CC   | AA   | GA   | TT   | CT   | TT   | TT   | GG   | GG   | TT   | AA   | AA   |
| # 3     | Oral cavity   | no   | no   | no   | no   | GG   | GG   | GG   | GG   | TT   | CC   | GG   | TT   | TT   | CC   | AA   | AA   | AA   |
| # 5     | Oral cavity   | AA   | TT   | TT   | TT   | GG   | AG   | GG   | CC   | CT   | AA   | GG   | TT   | CT   | TC   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 6     | Tongue        | GG   | TT   | TT   | TT   | GG   | AA   | GG   | CC   | CC   | AA   | GG   | TT   | CT   | TT   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 4     | Oral cavity   | GG   | CT   | CT   | TT   | GG   | AG   | GG   | CG   | TT   | AC   | GG   | TT   | TT   | CC   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 9     | Oral cavity   | GG   | CC   | CC   | AA   | GG   | GG   | GG   | GG   | TT   | CC   | GG   | TT   | TT   | CC   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 8     | Tracheal secretion | GG   | CC   | CC   | AA   | GG   | AG   | GG   | CC   | CC   | AA   | GG   | TT   | CT   | TT   | TT   | GG   | GG   | TT   | AA   | TT   |
| medium  |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
| # 13    | Foot           | GA   | TT   | TT   | TT   | GG   | AA   | GG   | CC   | CC   | AA   | GG   | TT   | CT   | TT   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 1     | Oral cavity   | GG   | CC   | CC   | AA   | GG   | GG   | GG   | GG   | CC   | AA   | AA   | TT   | TT   | TT   | TT   | TT   | GG   | AA   | TT   | TT   |
| # 10    | Inguinal      | GG   | CC   | CC   | TT   | GG   | AA   | GG   | CC   | CC   | CT   | AA   | GG   | TT   | TT   | CC   | AA   | AA   | AA   | CC   | AA   |
| # 2     | Oral cavity   | GA   | TT   | TT   | TT   | GG   | AG   | GA   | CC   | CC   | AA   | GA   | TG   | CT   | TT   | TT   | GG   | GG   | TT   | AA   | TT   |
| # 12    | Foot           | GA   | CT   | CC   | CC   | GG   | AG   | GG   | CC   | CC   | TC   | AA   | GG   | TT   | TT   | CC   | TG   | GG   | TT   | AA   | TT   |
| # 7     | Palate         | AA   | TT   | TT   | TA   | GG   | AA   | GG   | CC   | CC   | AA   | GG   | TT   | CT   | TC   | TT   | GG   | GG   | TT   | AA   | TT   |
| high    |                |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|         |                | n    | 6    | 12   | 11   | 9    | 26   | 12   | 1    | 8    | 7    | 4    | 4    | 1    | 17   | 11   | 4    | 4    | 6    | 4    | 2    | 2    |
|         | strains hom    | 2    | 5    | 5    | 4    | 13   | 3    | 0    | 3    | 3    | 2    | 1    | 0    | 5    | 4    | 2    | 2    | 3    | 2    | 1    | 1    |
|         | strains het    | 2    | 2    | 1    | 1    | 0    | 6    | 1    | 2    | 1    | 0    | 2    | 1    | 7    | 3    | 0    | 0    | 0    | 0    | 0    |

doi:10.1371/journal.pone.0113192.t001
and in three isolates as a heterozygous variant. The Ile111Ser exchange appeared as heterozygous variation in one single isolate (Table 1). The PRA1 gene had an overall nucleotide exchange rate of 1.78%, with nine synonymous and seven non synonymous exchanges. Thus, GPM1 and PRA1 represent conserved fungal immune evasion genes.

Surface expression levels of Gpm1 and Pra1 in the clinical C. albicans isolates

To identify additional variables relevant for fungal immune fitness, we next analyzed surface expression levels of the two immune escape proteins. Gpm1 expression levels varied among in the clinical strains and ranged from 512 to 4200 (MFI). Pra1 expression levels ranged from 12393 (J#11) to 41282 (J#7) (MFI) (Fig. 2A-2C). Thus Gpm1 surface levels varied by a factor of 8.2 and that of Pra1 by 3.3.

Fig 2. Gpm1 and Pra1 expression levels vary among the C. albicans isolates. Gpm1 (A) and Pra1 (B) surface expression of the thirteen clinical C. albicans isolates. Each C. albicans isolate as well as the reference strain SC5314 was incubated in Gpm1- or Pra1 specific anti-serum and after washing bound antibodies were detected by flow cytometry using secondary Alexa Fluor-488, or Alexa Fluor-647 labeled goat-anti rabbit serum. Control means that SC5314 was incubated with pre-immune serum instead of anti Pra1 or anti Gpm1 sera. Each panel shows representative results of three independent experiments. (C) Median fluorescence intensity of Gpm1 and Pra1 from three independent experiments. The data shown represent mean values ± SD of three separate experiments. (D) Correlation of Gpm1- and Pra1 surface levels for the in thirteen clinical isolates and SC5314. When further analyze the expression level of Candida Gpm1 and Pra1 within these thirteen clinical isolates, we found that Gpm1 and Pra1 surface levels correlated with each other. Most of the high Gpm1 expressing Candida isolates had relatively high Pra1 surface levels (Fig. 2D). Similarly the medium or low Gpm1 expressing strains had medium/low Pra1 surface levels, respectively. The exceptions were isolates J#5 and J#9, of which both had low or high Gpm1, but medium Pra1 levels (Table 2). Thus Gpm1 and Pra1 surface levels are variable among the clinical isolate and surface expression levels of the two fungal immune evasion proteins correlate with each other to a great extent.

doi:10.1371/journal.pone.0113192.g002
The median fluorescence intensities for both proteins’ expression level are shown in. Due to different surface expression level of both proteins, these thirteen strains were divided into three groups: low (Marked in light grey), medium (marked in dark grey) and high (marked in black). Six clinical isolates (two from the low group, two from the medium group and another two from the high group according to Pra1 surface expression) were selected for further function analysis. MFI (mean fluorescence intensity) Gpm1 and Pra1 bind several human innate immune regulators. Gpm1 binds human Factor H and plasminogen, but not C4BP. Pra1 binds Factor H, C4BP and plasminogen [25,35]. In order to define whether Gpd2 and Pra1 surface levels affect fungal immune fitness, firstly the clinical strains were grouped as low (MFI of Pra1 < 17500, two isolates), medium (MFI of Pra1 17501–30000, six isolates) and high expressing strains (MFI of Pra1 > 30000, five isolates) (Table 2) according to their Gpm1/Pra1 surface levels. Two strains were selected from each group and tested for (i) regulator binding, (ii) survival in complement active, Factor H depleted human serum, (iii) adhesion to human endothelial cells, as well as (iv) for their effect on complement activation.

### Binding of the human immune regulators Factor H, C4BP and plasminogen to clinical C. albicans isolates

To defined how Gpm1- and Pra1 surface levels contribute to regulator attachment, the selected low (J#3, J#11), medium (J#4, J#6) and high expressing isolates (J#7, J#10) were challenged with NHS and after washing attached Factor H, C4BP as well as plasminogen was evaluated by flow cytometry. Each strain bound all three human plasma regulators, however the regulators bound with different intensity. To allow a direct comparison, regulator binding to the reference strain SC5314 was set to 100%. Factor H bound to the low expressing isolates, J#3 & J#11 with low (i.e. 88%, 79%), to the medium expressing strains, Jn#4 & J#6 with medium (i.e. 96%,
and to the high expressing isolates, J#7 & J#10, with high intensity (i.e. 133%, 122%). Thus surface attachment of the human complement regulator Factor H varied by ca. 44% and correlated with Gpm1- and Pra1 surface levels (Fig. 3A).

In addition, also plasminogen binding varied. Plasminogen bound with moderate intensity to the low expressing strains, i.e. 96% and 78%, with higher intensity to the medium strains, i.e. 100% and 97% and with strongest intensity to the high expressing strains i.e. 101% and 119%. The difference between the high and low expression strain is ca. 23% (Fig. 3C). Thus the tested three human complement regulators bound with different intensity to the clinical C. albicans isolates and the intensity of regulator binding correlated with Gpm1- and Pra1 surface levels.

**Immune fitness of the C. albicans isolates**

In order to define how Gpm1 and Pra1 surface levels and regulator attachment contribute to fungal immune fitness, the clinical C. albicans isolates were first challenged with normal
human serum and after incubation the cell survival was evaluated. The number of \textit{C. albicans} cells at time zero was set 100%. All clinical isolates survived in NHS and no significant differences were detected (data not shown). We interpreted that Factor H as the central complement inhibitor when attached to the fungal surface protects Candida from complement damage. To further compare the immune fitness of the various fungal isolates in the absence of Factor H, and their survival in Factor H depleted complement active human serum were analyzed, both low expressing strains showed relative poor survival, as 61% and 52% of the yeast cells were recovered. The medium expressing isolates, had a good (69% and 79%) and both high expressing isolates had an even better survival (98% and 92%) (Fig. 4). The difference in survival between high and low expressing isolates corresponds to ca. 40%. These data demonstrate that the Factor H acquired by the fungal pathogens contributes to a significant extent for immune escape and that addition role of Pra1 and Gpm1 control complement attack.

Both adhesion to and invasion into human endothelial cells are critical for fungal survival in the infected host and for pathogenicity [29,45,46]. To monitor fungal adhesion/invasion to human endothelial cells the clinical isolate J#7 was co-cultivated with human endothelial cells (HUVEC). After washing, the Candida cells were stained with a cell-wall reacting anti-serum and the human cells with DAPI and the cells were analyzed by laser scanning microscopy (Fig. 5A). Upon incubation Candida yeast cells adhered to the human cells, hyphae formation was observed and Candida hyphae invaded into the human endothelial cells.

This approach allowed to compare infection of the various fungal isolates to human endothelial cells and to assay whether Gpm1/Pra1 surface levels affect interaction with human endothelial HUVEC cells. The six selected clinical isolates showed different rates of adhesion and invasion. Both low expression strains (J#3 and J#11) had relatively weak infection ability with 8 or 13% of the human cells appearing as double positive cells. The medium expressing isolates
(J#4 and J#6) bound to 25 and 20% of the human cells and the high expressing isolates (J#7 and J#10) interacted almost better, i.e. 22 and 30%. Thus the two high expressing clinical C. albicans isolates were more efficient in contacting human endothelial cells by about 60% than the low expressing isolates, indicating that the fungal surface proteins Gpm1 and Pra1 are relevant for contact with human cells and Gpm1- Pra1 surface levels contribute to fungal interaction with human endothelial cells.
Secretion levels of Pra1

Surface levels of Gpm1 and Pra1 varied among the clinical isolates. In addition Pra1, but not Gpm1, is secreted into the culture medium [34]. Therefore we analyzed and compared Pra1 levels in the culture medium. Culture supernatant was collected after 24 h, separated by SDS-PAGE, transferred to a membrane and Pra1 levels were detected by rabbit Pra1 antiserum, followed by a HPR swine anti-rabbit serum as a secondary antibody. Pra1 was detected as a 60 kDa protein in culture supernatant derived from medium (lanes 3 and 4) and of high expression Gpm1/Pra1 strains (lanes 6 and 7). The additional bands of higher molecular mass and of slower mobility (arrow heads), represent Pra1 in complex with additional soluble proteins. Pra1 was not detectable in the culture supernatant derived from the two low Gpm1/Pra1 expressing strains (lanes 2 and 3). The arrow shows the 60 kDa Pra1 monomer and the position of the additional dimmer or multimeric forms and Pra1 containing complexes are likely indicated by the arrow heads. (B) Supernatant derived from the clinical C. albicans isolates blocked C3b/iC3b deposition on the yeast surface. The selected C. albicans clinical isolates were cultivated in YPD medium overnight, and culture supernatant derived from 5x10^6 cells of each isolate was added to NHS (7.5%) diluted in Mg-EGTA, then heat treated C. albicans were challenged with this serum-supernatant mixture for 30 min at 37°C. Following washing C3b/iC3b surface deposition was analyzed by flow cytometry using goat anti-C3 serum. Candida cells treated in the absence of NHS are shown as control. The histogram shown here is one representative experiment out of three performed. (C) The mean values of median fluorescence intensity of C3b/iC3b from three independent experiments. C3b/iC3b levels on the surface of cells incubated in NHS were set 100%. The mean values of each group, i.e. the low, medium or high Gpm1/Pra1 expressing isolates are indicated by the crossed circle in the middle of each group. The mean values of median fluorescence intensity from three independent experiments ± SD are shown.

doi:10.1371/journal.pone.0113192.g006

Fig 6. Pra1 secretion and effect of secreted Pra1 on C3b/iC3b surface deposition. (A) Presence of Pra1 in the culture supernatant. Culture supernatant (YPD medium following overnight culture) of the selected clinical C. albicans strains (1x10^6 cells) was separated by SDS-PAGE, transferred to a membrane and Pra1 levels were detected by rabbit Pra1 antiserum, followed by a HPR swine anti-rabbit serum as a secondary antibody. Pra1 was detected as a 60 kDa protein in culture supernatant derived from medium (lanes 3 and 4) and of high expression Gpm1/Pra1 strains (lanes 6 and 7). The additional bands of higher molecular mass and of slower mobility (arrow heads), represent Pra1 in complex with additional soluble proteins. Pra1 was not detectable in the culture supernatant derived from the two low Gpm1/Pra1 expressing strains (lanes 2 and 3). The arrow shows the 60 kDa Pra1 monomer and the position of the additional dimmer or multimeric forms and Pra1 containing complexes are likely indicated by the arrow heads. (B) Supernatant derived from the clinical C. albicans isolates blocked C3b/iC3b deposition on the yeast surface. The selected C. albicans clinical isolates were cultivated in YPD medium overnight, and culture supernatant derived from 5x10^6 cells of each isolate was added to NHS (7.5%) diluted in Mg-EGTA, then heat treated C. albicans were challenged with this serum-supernatant mixture for 30 min at 37°C. Following washing C3b/iC3b surface deposition was analyzed by flow cytometry using goat anti-C3 serum. Candida cells treated in the absence of NHS are shown as control. The histogram shown here is one representative experiment out of three performed. (C) The mean values of median fluorescence intensity of C3b/iC3b from three independent experiments. C3b/iC3b levels on the surface of cells incubated in NHS were set 100%. The mean values of each group, i.e. the low, medium or high Gpm1/Pra1 expressing isolates are indicated by the crossed circle in the middle of each group. The mean values of median fluorescence intensity from three independent experiments ± SD are shown.

doi:10.1371/journal.pone.0113192.g006

Secrecion levels of Pra1

Surface levels of Gpm1 and Pra1 varied among the clinical isolates. In addition Pra1, but not Gpm1, is secreted into the culture medium [34]. Therefore we analyzed and compared Pra1 levels in the culture medium. Culture supernatant was collected after 24 h, separated by SDS-PAGE, transferred to a membrane and Pra1 was identified by Western blotting. Pra1 was detected as a 60 kDa band in the supernatant of the medium- and the high expressing isolates, as well as in culture supernatant of the reference strain SC5314 (Fig. 6A). Pra1 was not detectable in supernatant collected from both low expressing isolates, J#3 and J#11 (Fig. 6A, lanes 3 and 2). Thus the medium and high, but not the low expressing Pra1 expression strains have
detectable levels of Pra1 in the culture supernatant. Released Pra1 level correlates with the expression level at the yeast surface. The band with mobility of around 60kDa is the Pra1 protein, the upper bands are likely the dimeric or multimeric variant of Pra1, or even complexes of Pra1 with other Candida proteins.

In order to define whether Pra1 levels in the supernatant correlate with that of other fungal virulence factors, secreted aspartyl proteases 1–3 (mainly Sap2) level were evaluated in Western blotting [47,48]. The low Pra1 expressing strain J#3, but not isolate J#11, one high Pra1 expressing isolate J#10 and the reference strain SC5314 had no detectable levels of Sap2 in YPD-culture supernatant. Sap2 was released by both medium-, one low- and one high Pra1 expressing strain isolates (S1 Fig.). Thus Sap2 release varied among the isolates and did not correlate with Pra1 levels.

Secreted Pra1 affects C3b/iC3b surface deposition

Soluble Pra1 inhibits C3 activation and C3 processing and contributes to fungal survival [34]. Given the different Pra1 levels in the culture supernatant of the tested clinical strains, we next asked whether Pra1 secreted into the culture supernatant influences C3b/iC3b deposition on the fungal surface. To this end, culture supernatant derived from the low, medium and high expressing C. albicans isolates was first added to NHS and then used to challenge heat treated C. albicans. Following incubation and extensive washing, C3b/iC3b deposition on the fungal surfaces was evaluated by flow cytometry. In this case the median fluorescent intensities of surface deposited C3b/iC3b varied. Supernatant derived from the low Pra1 secreting isolates resulted in high C3b deposition. Supernatant derived from the medium and high Pra1 secreting isolates caused lower C3b surface deposition (Table 3). C3b/iC3b surface level challenged with NHS in the absence of the C. albicans supernatant was set as 100% (i.e. MFI 10946) (Fig. 6B, green curve). C3b/iC3b surface levels upon treatment with supernatant derived from the low expressing isolates (J#3 and J#11) was reduced by 58% and 35%, for the medium expressing isolates (J#4 and J#6) by 57% and 45%, and for the high expressing strains (J#7 and J#10) by 70% and 57%, respectively (Fig. 6C). High Pra1 levels blocked C3b/iC3b surface deposition by about 27% better, compared to the low Pra1 expressing strain. Thus Pra1 levels can be considered as a biomarker on complement control as evidenced by C3b/iC3b surface deposition onto the fungal surface.

The mean fluorescence intensities of the C3b/iC3b surface deposition from one experiment shown in Fig. 6B are shown in Table 3. Due to different surface expression level of Gpm1/Pra1,

| Isolate | IC3b (MFI) |
|---------|------------|
| # 11    | 7290       |
| # 3     | 6116       |
| # 6     | 4397       |
| # 4     | 5239       |
| # 10    | 5624       |
| # 7     | 4678       |
| SC5314  | 4552       |
| Control | 172        |
| serum   | 10947      |
| Gelatine| 11235      |

doi:10.1371/journal.pone.0113192.t003
six clinical isolates (J#3 and J#11, J#4 and J#6 as well as J#7 and J#10) show different ability on complement control as indicated by different surface C3b/iC3b deposition.

**Discussion**

Microbial pathogens modulate and control the innate immune responses in order to survive in an immunocompetent host. Pra1 and Gpm1 are two central fungal complement evasion proteins of *C. albicans*. Here we analyzed sequence variation, as well as expression levels of these two fungal immune evasion proteins among clinical *C. albicans* isolates. The nucleotide sequence revealed *GPM1* and *PRA1* as conserved fungal immune evasion genes. Both immune evasion proteins were expressed with different levels at the fungal surface. In addition, Pra1 secretion levels varied. The surface levels of Gpm1 and Pra1 correlated with each other. The level of these two immune evasion proteins influenced: (i) fungal binding of the human plasma regulators, Factor H, C4BP and plasminogen, (ii) fungal survival in complement active, Factor H depleted human serum, (iii) fungal adhesion to human endothelial cells, and (iv) also C3b/iC3b deposition onto the fungal surface.

*Candida GPM1* and *PRA1* represent rather conserved fungal genes, have little sequence variation and show gene variation rates of 0.54 and 1.78% in the thirteen clinical *C. albicans* isolates tested. The allelic frequencies of the four synonymous nucleotide exchanges within the *GPM1* gene ranged from 0.31 to 0.50. The allelic frequency for each of the sixteen exchanges of the *PRA1* gene ranged from 0.08 to 1.0. The *PRA1* gene had seven non synonymous exchanges, and four of these exchanges cause a conservative amino acid replacement. The three likely more relevant exchanges at positions 25, 105 and 111 were represented with allelic frequencies of 1.0, 0.23 and 0.07, respectively. The two exchanges at position 25 and 105, i.e. Asn25 and Gly105, replace a neutral amino acid a charged and acidic Asp residue. In addition Ile111 is changed to a hydrophobic Ser residue (Fig. 1). All tested clinical isolates and the tested strain SC5314 had nucleotide G73, resulting in Asp25. Genbank reports for strain SC5314 at this position two different nucleotides. The initial sequence reports A73 (accession no. U84261), coding for Asn25 [49], and also the variant G73 (Asp25) is reported [50].

Candida Gpm1 and Pra1, like other pathogen derived complement evasion proteins bind many human plasma proteins, and attach several of the host immune regulators. In general terms complement evasion proteins of pathogenic microbes present two major classes: The first group includes immune evasion proteins which have a conserved sequence repertoire, and these proteins show no or rather little sequence diversity. Proteins of this conserved group, include Gpm1 and Pra1, the two fungal proteins studied here, the CRASPs proteins of *Borrelia* species and also the fHbp protein of group B *N. meningitidis* isolates [42]. However group II complement evasion proteins, have a high degree of sequence diversity and a modular structure, but maintain conserved binding characteristics for human complement regulators and for host proteins. Examples for such highly polymorphic microbial proteins are, the M proteins family of *S. pyogenes* and the PspC protein family of *S. pneumonia* [38,39,40,41].

At present the regulator binding regions within Gpm1 and Pra1 have neither been localized, nor mapped to certain protein regions. The *PRA1* sequence includes an N-terminal cysteine-rich domain, an internal collagen-like domain, a zinc binding region and a non collagen type region within C-terminus [49,51]. The collagen-like domain has been proposed to be relevant for anchoring, attaching and colonization of the fungus to human extra-cellular matrices.

Expression levels of fungal complement evasion proteins vary among the isolates but correlate with regulator attachment and with survival in human Factor H depleted serum. The clinical *C. albicans* isolates with high Gpm1/Pra1 levels bound the protective human regulators more efficiently. The high expressing isolates bound about 50% more Factor H and C4BP to
their surface than the low expressing isolates. Plasminogen binding was also increased by 23% (Fig. 3). Upon challenge with normal human serum, all tested C. albicans survived and no significant difference was detected. Thus indicating that surface attached Factor H, although with different levels efficiently protected these isolates from alternative complement attack [17,52]. However, the high expressing clinical C. albicans isolates control the complement challenge more efficiently and survived better upon challenge by human Factor H depleted serum, i.e. 98 and 92.1%. Both low expression strains were more susceptible to this serum challenge and in this case only 60.5 or 52% of the cells survived (Fig. 4). Thus Gpm1 and Pra1, likely in combination with other fungal virulence factors contribute to fungal immune fitness and to fungal survival.

C. albicans as a tissue residing pathogen not only needs to block the complement barrier, but also to cross and to penetrate endothelial- as well as epithelial cell layers. Thus after crossing the complement barrier, the next steps critical for fungal infection are adhesion and invasion to human endothelial cells, breaching the endothelial barrier and dissemination into deeper tissue layers [45]. The analyzed clinical isolates showed a different activity for endothelial cell adhesion and invasion and this difference is influenced and modulated by Gpm1 and Pra1 surface levels. The high expressing Candida isolates showed about 60% better infection to the human endothelial cells, as compared to the low expressing isolates.

Pra1 levels in the culture supernatant varied among the clinical strains and influenced C3b/iC3b surface deposition. Apparently Pra1 is not the only fungal C3 inhibitor. Supernatant of isolates J#3 and J#11, that both lacked detectable Pra1 levels also blocked C3b/iC3b surface opsonization (Fig. 6). Such additional fungal C3 inhibitory or degrading proteins include Sap2, which as shown here is however differently regulated from Pra1. C. albicans uses a set of virulence factors or virulence determinants to control and to modulate host complement attack. During the various infection stages the individual virulence determinants control fungal immune evasion, adjust cell adherence and tissue interaction (Fig. 6).

C. albicans, similar to many other Gram positive or Gram negative pathogenic bacteria expresses several Factor H-, C4BP- and/or plasminogen binding evasion proteins. At present, four Factor H (Gpm1, Pra1, Hgt1p, Gpd2), two C4BP (Pra1 and Hgt1p), and ten plasminogen binding proteins (Gpm1, Pra1, Gpd2, alcohol dehydrogenase, thioredoxin peroxidase, catalase, transcription elongation factor, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase and fructose bisphosphate aldolase) have been identified for C. albicans. Such an acquisition of multiple host complement regulators and also of other human immune effector proteins is a common and important escape strategy that is used by many, likely even by all pathogenic microbes. The levels of surface attached host regulators, Factor H, C4BP and plasminogen by different clinical isolates correlated in a positive manner, with Gpm1- and Pra1 expression levels at the fungal surface. Although a clear correlation existed, there are also some variations, showing that additional proteins and factors contribute to fungal immune evasion.

Taken together, GPM1 and PRA1 of C. albicans, are rather conserved fungal immune evasion genes which are expressed at different levels among the tested clinical isolates, influencing fungal immune fitness. These fungal evasion proteins influence many steps of the infection process, in particular acquisition of human complement regulators, survival of complement challenge by active, Factor H depleted human serum, adhesion and invasion to human endothelial cells, as well as blockade of surface C3b/iC3b deposition. C. albicans expresses several complement and immune escape proteins at the same time, explaining why a targeting or an inhibiting approach of a single gene does not cause substantial changes in the immune response. Therefore approaches that aim to direct and inactivate all fungal escape proteins at the same time seem more appropriate.
Supporting Information

S1 Fig. Levels of Candida Sap1/Sap2/Sap3 in the culture supernatant of the selected clinical C. albicans strains. The selected C. albicans clinical strains and of the reference SC5314 strain were cultivated in YPD medium overnight at 30°C. Culture supernatant derived from 1x10^6 cells of each C. albicans strain was separated by SDS-PAGE and transferred to a membrane and developed with a polyclonal rabbit anti Sap1/Sap2/Sap3 serum, followed by a HPR swine anti-rabbit serum as a secondary antibody. The 42 kDa Sap2 band was detected in culture supernatant derived from one low, two medium and one high Gpm1/Pra1 expressing isolate. The figure shows a representative experiment out of three performed.

Acknowledgments

Part of the data was presented at the XXII International Complement Workshop, in Basel, Switzerland, 2008. We thank Prof. Bernhard Hube for providing polyclonal rabbit anti Saps1/2/3 serum. We thank Prof. Anna M. Blom for providing polyclonal rabbit anti C4BP serum.

Author Contributions

Conceived and designed the experiments: SL UCH CS PFZ. Performed the experiments: SL UCH CM. Analyzed the data: SL UCH CM CS PFZ. Wrote the paper: SL CS PFZ.

References

1. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS (2001) Traversal of Candida albicans across human blood-brain barrier in vitro. Infect Immun 69: 4536–4544. PMID:11401997
2. Olczak-Kowalczyk D, Pawlowska J, Garczewska B, Smirka E, Grenda R, et al. Oral candidiasis in immunosuppressed children and young adults after liver or kidney transplantation. Pediatr Dent 32: 189–194. PMID:20557701
3. Alves SH, Da Matta DA, Azevedo AC, Loreto ES, Boff E, et al. (2006) In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. Mycoses 49: 220–225. PMID:16681814
4. Yamamoto T [Oral candidiasis: clinical features and control]. Rinsho Byori 58: 1027–1034. PMID:21077293
5. Harrriott MM, Lilly EA, Rodriguez TE, Fidel PL Jr., Noverr MC Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156: 3635–3644. doi:10.1099/mic.0.039354-0 PMID:20705667
6. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, et al. (2003) Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 22: 254–257. PMID:12709840
7. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172–1177. PMID:14557960
8. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, et al. (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37: 634–643. PMID:12942393
9. Iannitti RG, Carvalho A, Romani L From memory to antifungal vaccine design. Trends Immunol.
10. Zipfel PF (2009) Complement and immune defense: from innate immunity to human diseases. Immunol Lett 126: 1–7. doi: 10.1016/j.imlet.2009.07.005 PMID:19616581
11. Zipfel PF, Mihlan M, Skerka C (2007) The alternative pathway of complement: a pattern recognition system. Adv Exp Med Biol 598: 80–92. PMID:17892206
12. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729–740. doi: 10.1038/nri2620 PMID:19730437
13. Skerka C, Kuhn S, Gunther K, Lingelbach K, Zipfel PF (1993) A novel short consenss peptide-containing molecule is related to human complement factor H. J Biol Chem 268: 2904–2908. PMID:8428964
14. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S (1999) The factor H protein family. Immunopharmacology 42: 53–60. PMID:10408366
15. Skerka C, Hellwage J, Weber W, Tilkorn A, Buck F, et al. (1997) The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins. J Biol Chem 272: 5627–5634. PMID: 9038172

16. Skerka C, Timmann C, Horstmann RD, Zipfel PF (1992) Two additional human serum proteins structurally related to complement factor H. Evidence for a family of factor H-related genes. J Immunol 148: 3313–3318. PMID: 1535657

17. Skerka C, Horstmann RD, Zipfel PF (1991) Molecular cloning of a human serum protein structurally related to complement factor H. J Biol Chem 266: 12015–12020. PMID: 1711047

18. Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, et al. (1999) Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett 462: 345–352. PMID: 10622723

19. Zipfel PF, Wurzner R, Skerka C (2007) Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol Immunol 44: 3850–3857. PMID: 17768102

20. Meri T, Hartmann A, Lenk D, Eck R, Wurzner R, et al. (2002) The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 70: 5185–5192. PMID: 12183569

21. Meri T, Blom AM, Hartmann A, Lenk D, Meri S, et al. (2004) The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun 72: 6633–6641. PMID: 15501796

22. Behnsen J, Hartmann A, Schmaler J, Gehrke A, Brakhage AA, et al. (2008) The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun 76: 820–827. PMID: 18039838

23. Zipfel PF, Skerka C, Kupka D, Luo S (2011) Immune escape of the human facultative pathogenic yeast Candida albicans: the many faces of the Candida Pra1 protein. Int J Med Microbiol 301: 423–430. doi: 10.1016/j.ijmm.2011.04.010 PMID: 21565550

24. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, et al. (2007) Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. J Biol Chem 282: 37537–37544. PMID: 17959597

25. Luo S, Poltermann S, Kunert A, Rupp S, Zipfel PF (2009) Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, FHL-1 and plasminogen-binding surface protein. Mol Immunol 47: 541–550. doi: 10.1016/j.molimm.2009.07.017 PMID: 19850343

26. Luo S, Hoffmann R, Skerka C, Zipfel PF (2013) Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-, factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. J Infect Dis 207: 594–603. doi: 10.1093/infdis/jis718 PMID: 23204165

27. Lesiak-Markowicz I, Vogl G, Schwarzmueller T, Speth C, Lass-Florl C, et al. (2011) Candida albicans Hgt1p, a multifunctional evasion molecule: complement inhibitor, CR3 analogue, and human immuno-deficiency virus-binding molecule. J Infect Dis 204: 802–809. doi: 10.1093/infdis/jir455 PMID: 21844307

28. Crowe JD, Siewwright IK, Auld GC, Moore NR, Gow NA, et al. (2003) Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Mol Microbiol 47: 1637–1651. PMID: 12622818

29. Hammerschmidt S, Agarwal V, Kunert A, Haebich S, Skerka C, et al. (2007) The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol 178: 5848–5858. PMID: 17442969

30. Haupt K, Reuter M, van den Elen J, Burman J, Halbich S, et al. (2008) The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog 4: e1000250. doi: 10.1371/journal.ppat.1000250 PMID: 19112495

31. Kunert A, Losse J, Gruszin C, Huhn M, Kaendler K, et al. (2007) Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol 179: 2979–2988. PMID: 17709513

32. Kraicz P, Skerka C, Kirschfink M, Brade V, Zipfel PF (2001) Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur J Immunol 31: 1674–1684. PMID: 11385611

33. Meri T, Jokiranta TS, Hellwage J, Bialonski A, Zipfel PF, et al. (2002) Onchocerca volvulus microfilariae avoid complement attack by direct binding of factor H. J Infect Dis 185: 1767–1773. PMID: 12085326

34. Luo S, Hartmann A, Dahse HM, Skerka C, Zipfel PF (2010) Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3. J Immunol 185: 2164–2173. doi: 10.4049/jimmunol.1001011 PMID: 20644161
35. Luo S, Blom AM, Rupp S, Hipler UC, Hube B, et al. (2011) The pH-regulated antigen 1 of Candida albicans binds the human complement inhibitor C4b-binding protein and mediates fungal complement evasion. J Biol Chem 286: 8021–8029. doi:10.1074/jbc.M110.130138 PMID: 21212281

36. Soloviev DA, Fonzi WA, Sentandreu R, Pluskota E, Forsyth CB, et al. (2007) Identification of pH-regulated antigen 1 released from Candida albicans as the major ligand for leukocyte integrin alphaMbeta2. J Immunol 178: 2038–2046. PMID: 17277107

37. Haupt K, Kraicz P, Wallich R, Brade V, Skerka C, et al. (2007) Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis 196: 124–133. PMID: 17538892

38. Perez-Casal J, Price JA, Maguin E, Scott JR (1993) An M protein with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature-sensitive shuttle vector to deliver homologous sequences to the chromosome of S. pyogenes. Mol Microbiol 8: 809–819. PMID: 8355608

39. Johnsson E, Berggard K, Kotarsky H, Hellwage J, Zipfel PF, et al. (1998) Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. J Immunol 161: 4894–4901. PMID: 9794423

40. Hunter JC, K BW, McCoy MC, Quinn JF, Keller KE (1999) RESEARCH: Prospects for Preservation and Restoration of Riparian Forests in the Sacramento Valley, California, USA. Environ Manage 24: 65–75. PMID: 10341063

41. Iannelli F, Oggioni MR, Pozzi G (2002) Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 284: 63–71. PMID: 11891047

42. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, et al. (2010) Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 17: 919–929. doi:10.1128/CVI.00027-10 PMID: 20375242

43. Gillum AM, Tsay EY, Kirsch DR (1984) Isolation of the Candida albicans gene for orotidine-5'-phosphoribosyltransferase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198: 179–182. PMID: 6394964

44. Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, et al. (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512–1514. PMID: 18006700

45. Filler SG, Sheppard DC (2006) Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2: e129. PMID: 17196036

46. Pandiripally V, Wei L, Skerka C, Zipfel PF, Cue D (2003) Recruitment of complement factor H-like protein 1 promotes intracellular invasion by group A streptococci. Infect Immun 71: 7119–7128. PMID: 14638802

47. Schaller M, Bein M, Korting HC, Baur S, Hamm G, et al. (2003) The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infect Immun 71: 3227–3234. PMID: 12761103

48. Tongchusak S, Leelayuwat C, Brusic V, Chaiyaroj SC (2008) In silico prediction and immunological validation of common HLA-DRB1-restricted T cell epitopes of Candida albicans secretory aspartyl proteinase 2. Microbiol Immunol 52: 231–242. doi:10.1111/j.1348-0421.2008.00032.x PMID: 18426398

49. Sentandreu M, Etorza MV, Sentandreu R, Fonzi WA (1998) Cloning and characterization of PRA1, a gene encoding a novel pH-regulated antigen of Candida albicans. J Bacteriol 180: 282–289. PMID: 9440517

50. Citiulo F, Jacobsen ID, Miramon P, Schild L, Brunke S, et al. (2012) Candida albicans scavenges host zinc via PRA1 during endothelial invasion. PLoS Pathog 8: e1002777. doi:10.1371/journal.ppat.1002777 PMID: 22761575

51. Muller HJ, Skerka C, Blionski A, Zipfel PF (1991) Clone pAT 133 identifies a gene that encodes another human member of a class of growth factor-induced genes with almost identical zinc-finger domains. Proc Natl Acad Sci U S A 88: 10079–10083. PMID: 1658795

52. Zipfel PF, Blionski A, Skerka C (1991) Induction of members of the IL-8/NAP-1 gene family in human T lymphocytes is suppressed by cyclosporin A. Biochem Biophys Res Commun 181: 179–183. PMID: 1720306